Articles by Disease (Hypotension )

JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?

Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 12
Page: 1098-1109
Author(s): Fabio P. S. Santos and Srdan Verstovsek

Reversible Michael Additions: Covalent Inhibitors and Prodrugs

Journal: Mini-Reviews in Medicinal Chemistry
Volume: 12
Page: 1330-1344
Author(s): Martin H. Johansson

Perspectives on Brain-Targeting Drug Delivery Systems

Journal: Current Pharmaceutical Biotechnology
Volume: 13
Page: 2310-2318
Author(s): Liangran Guo, Jinfeng Ren and Xinguo Jiang

Topical Fluoride for Preventing Dental Caries in Children and Adolescents

Journal: Current Pharmaceutical Design
Volume: 18
Page: 5532-5541
Author(s): Faith Y. Miller, Guglielmo Campus, Giovanna Giuliana, Maria R. Piscopo and Giuseppe Pizzo

PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update

Journal: Current Pharmaceutical Design
Volume: 18
Page: 5590-5606
Author(s): Serap Gur, Philip J. Kadowitz, Ege Can Serefoglu and Wayne J.G. Hellstrom

Drug Delivery Systems with Modified Release for Systemic and Biophase Bioavailability

Journal: Current Clinical Pharmacology
Volume: 7
Page: 282-317
Author(s): Sorin E. Leucuta

Comparative Bioavailability of Two Oral Formulations of Clozapine in Steady State Administered in Schizophrenic Volunteers Under Individualized Dose Regime

Journal: Current Clinical Pharmacology
Volume: 7
Page: 241-253
Author(s): Ney C. do Carmo Borges, Rafael B. Astigarraga, Carlos E. Sverdloff, Paulo R. Galvinas, Bruno C. Borges and Ronilson A. Moreno